Royalty Pharma plc
HealthcareNASDAQ:RPRX · NASDAQ Global Select
-$0.42 today
Vol 3.07M · Avg 3.65M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$2.4B of revenue converted into $827.6M of net income for the selected period. Gross margin is 100.0% and net margin is 33.4%, showing how much revenue survives after costs and taxes. EPS is $1.77, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4B +5.1% | $2.3B -3.9% | $2.4B +5.2% | $2.2B -2.3% | $2.3B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $2.4B +5.1% | $2.3B -3.9% | $2.4B +5.2% | $2.2B -2.3% | $2.3B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $452.0M +22500.0% | $2.0M -96.2% | $52.0M -70.6% | $177.1M -11.5% | $200.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $573.5M +142.3% | $236.7M -5.2% | $249.7M +9.9% | $227.3M +24.3% | $182.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $818.7M -15.7% | $971.1M +12.6% | $862.4M -55.3% | $1.9B +124.8% | $858.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.9M | $0 | $0 -100.0% | $5.7M -75.3% | $23.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.6B +5.1% | $1.6B -17.5% | $1.9B +345.4% | $423.7M -70.4% | $1.4B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 68.8% +0.0pp | 68.8% -11.4pp | 80.2% +61.2pp | 18.9% -43.5pp | 62.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.6B +20.7% | $1.3B -13.4% | $1.5B +385.9% | $307.1M -78.5% | $1.4B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 65.6% +8.5pp | 57.1% -6.3pp | 63.4% +49.6pp | 13.7% -48.8pp | 62.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $33.6M -29.0% | $47.3M -34.5% | $72.3M -7.7% | $78.3M +46.3% | $53.5M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $307.7M +36.4% | $225.5M +20.5% | $187.2M -0.4% | $188.0M +13.1% | $166.1M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$235.3M -713.3% | $38.4M -81.5% | $207.9M +370.0% | -$77.0M +59.4% | -$189.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.3B -0.5% | $1.3B -21.7% | $1.7B +639.0% | $230.1M -81.5% | $1.2B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 55.7% -3.1pp | 58.8% -13.4pp | 72.2% +61.9pp | 10.3% -43.9pp | 54.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | $770.9M -10.2% | $859.0M -24.3% | $1.1B +2549.5% | $42.8M -93.1% | $619.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | 32.4% -5.5pp | 37.9% -10.2pp | 48.2% +46.3pp | 1.9% -25.2pp | 27.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +21.4% | $2 -43.7% | $3 +3310.0% | $0 -93.3% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 -5.8% | $2 -24.5% | $3 +2430.0% | $0 -93.3% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $431.9M -3.2% | $446.0M -0.4% | $447.6M +2.2% | $438.0M +5.6% | $414.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $559.6M -5.8% | $594.0M -1.5% | $602.9M +6.7% | $564.9M +36.2% | $414.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
United Therapeutics Corporation
NASDAQ:UTHR
$23.17B
Incyte Corporation
NASDAQ:INCY
$21.68B
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.61B
Hologic, Inc.
HOLX
$16.97B
Genmab A/S
NASDAQ:GMAB
$15.40B
Tenet Healthcare Corporation
NYSE:THC
$15.04B
Exelixis, Inc.
NASDAQ:EXEL
$13.35B
Smith & Nephew plc
NYSE:SNN
$12.97B
Fresenius Medical Care AG & Co. KGaA
NYSE:FMS
$12.36B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.86B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does RPRX generate?
Royalty Pharma plc (RPRX) reported $2.38B of revenue in fiscal 2025.
Is RPRX profitable?
Royalty Pharma plc (RPRX) reported $770.95M of net income, with a net margin of 32.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.